The goal of the Analytical Cytometry Core (ACC) is to provide the COHCCC members, through its facilities, leading-edge equipment and experienced operators to measure properties of cells and their components, isolate those cells and their components and present the data acquired for internal analysis and external review. Flow cytometry instrumentation available through this core resource includes: 3 high speed cell sorters (MoFlo, BD FACS Aria SORP and BD FACS Aria 111), and 4 analytical cytometers (Cyan, Gallios, LSR Fortessa and C6). The flow cytometry instrumentation provides investigators with the tools to analyze and isolate cells at speeds of up to 20,000 cells/second based on multiple fluorescent labels (up to 18) and light scatter properties with high yield (up to 90% based on speed) and extreme purity (99%). Additionally, the BD Aha 11 SORP is contained in a biosafety cabinet and allows users to sort live (potentially infectious) samples. All instrumentation in the ACC is subject to either daily (sorters and Fortessa) or weekly (Gallios, CyAn, and C6) quality control assessment and routine preventive maintenance and calibration. All data generated in the ACC is available through the institutional cyber-infrastructure network for further analysis and preparation for presentation or publication. Network based data processing software is offered by the core and a Laboratory Information Management System (LIMS) is being developed to help track experiment related meta data and archived file retrieval. Another key role of ACC is to provide flow cytometry training from basic theory, experimental design, software usage and operation of the cytometers to COHCCC members.
The overall goal of the Analytical Cytometry Core facility is to provide leading-edge equipment and experienced operators to measure properties of cells and their components, isolate those cells and present the data acquired for analysis and review. This goal promotes the Cancer Center's mission of developing innovative new disease-fighting strategies in the battle against cancer.
|Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828|
|Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118|
|Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141|
|Yim, John H; Choi, Audrey H; Li, Arthur X et al. (2018) Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. Clin Cancer Res :|
|Wang, Tianyi; Fahrmann, Johannes Francois; Lee, Heehyoung et al. (2018) JAK/STAT3-Regulated Fatty Acid ?-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab 27:136-150.e5|
|Magilnick, Nathaniel; Boldin, Mark P (2018) Molecular Moirai: Long Noncoding RNA Mediators of HSC Fate. Curr Stem Cell Rep 4:158-165|
|Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171|
|Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520|
|Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328|
|Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2018) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs 41:506-512|
Showing the most recent 10 out of 1396 publications